The company’s latest drug development data on the use of AverTox® (galantamine) as a pretreatment against soman nerve agent was presented by CEO, Bill Basinger at the June 2016 NINDS CounterACT meeting hosted by the University of California, Davis. The compelling results of this pivotal study in NHPs demonstrate that oral pretreatment use of AverTox significantly improves survival over the use of current standard of care drugs alone. Pharmacokinetics data collected during the study have allowed the determination of an equivalent dose of AverTox to be used to effectively protect humans from exposure to this nerve agent.